BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//DataCutoff//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:DataCutoff · $1093.HK readouts
X-WR-CALDESC:Clinical-trial primary completion dates from ClinicalTrials.go
 v\, refreshed nightly by DataCutoff. Not investment advice.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07256509-pcd@datacutoff.com
DTSTAMP:20261118T142521Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:SYS6010 readout (P2) · CSPC Megalith Biopharmaceutical Co.\,Ltd. $
 1093.HK
DESCRIPTION:A Study of SYS6010 Combined With Osimertinib Versus Osimertinib
  Alone as Neoadjuvant Therapy for Patients With EGFR Mutation-positive Res
 ectable Non-squamous Non-small Cell Lung C…\n\nPrimary completion date: 
 2026-11-30 (estimated)\nPhase 2 · Oncology · Non-Small Cell Lung Cancer\
 nEnrollment: 120 · Sites: 0\n\nPrimary completion = last participant's pr
 imary-endpoint data collected\; topline results usually follow weeks to mo
 nths later. Sponsor-reported\, often an estimate. Not investment advice.\n
 \nhttps://datacutoff.com/radar.html?nct=NCT07256509\nhttps://clinicaltrial
 s.gov/study/NCT07256509
URL:https://datacutoff.com/radar.html?nct=NCT07256509
CATEGORIES:Oncology,Phase 2
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07376382-pcd@datacutoff.com
DTSTAMP:20261118T142521Z
DTSTART;VALUE=DATE:20261212
DTEND;VALUE=DATE:20261213
SUMMARY:SYNSTAR-02 readout (P3) · CSPC Megalith Biopharmaceutical Co.\,Ltd
 . $1093.HK
DESCRIPTION:A Phase Ⅲ Clinical Study of SYS6010 in Combination With Osime
 rtinib in Patients With Locally Advanced or Metastatic NSCLC\n\nPrimary co
 mpletion date: 2026-12-12 (estimated)\nPhase 3 · Other · NSCLC\nEnrollme
 nt: 680 · Sites: 0\n\nPrimary completion = last participant's primary-end
 point data collected\; topline results usually follow weeks to months late
 r. Sponsor-reported\, often an estimate. Not investment advice.\n\nhttps:/
 /datacutoff.com/radar.html?nct=NCT07376382\nhttps://clinicaltrials.gov/stu
 dy/NCT07376382
URL:https://datacutoff.com/radar.html?nct=NCT07376382
CATEGORIES:Other,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07940075-pcd@datacutoff.com
DTSTAMP:20261118T142521Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:SYH2062 readout (P2) · CSPC Zhongnuo Pharmaceutical (Shijiazhuang)
  Co.\, Ltd. $1093.HK
DESCRIPTION:SYH2062 Injection in Participants With Mild to Moderate Essenti
 al Hypertension .\n\nPrimary completion date: 2027-01-31 (estimated)\nPhas
 e 2 · Cardio-Met · Mild to Moderate Primary Hypertension\nEnrollment: 36
 0 · Sites: 1\n\nPrimary completion = last participant's primary-endpoint 
 data collected\; topline results usually follow weeks to months later. Spo
 nsor-reported\, often an estimate. Not investment advice.\n\nhttps://datac
 utoff.com/radar.html?nct=NCT07940075\nhttps://clinicaltrials.gov/study/NCT
 07940075
URL:https://datacutoff.com/radar.html?nct=NCT07940075
CATEGORIES:Cardio-Met,Phase 2
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07354659-pcd@datacutoff.com
DTSTAMP:20261118T142521Z
DTSTART;VALUE=DATE:20270310
DTEND;VALUE=DATE:20270311
SUMMARY:A zoster mRNA vaccine SYS6017 readout (P2) · CSPC Megalith Biophar
 maceutical Co.\,Ltd. $1093.HK
DESCRIPTION:Immunogenicity and Safety of SYS6017 in the Participants Aged 4
 0 Years and Above\n\nPrimary completion date: 2027-03-10 (estimated)\nPhas
 e 2 · Infectious · Herpes Zoster\nEnrollment: 800 · Sites: 0\n\nPrimary
  completion = last participant's primary-endpoint data collected\; topline
  results usually follow weeks to months later. Sponsor-reported\, often an
  estimate. Not investment advice.\n\nhttps://datacutoff.com/radar.html?nct
 =NCT07354659\nhttps://clinicaltrials.gov/study/NCT07354659
URL:https://datacutoff.com/radar.html?nct=NCT07354659
CATEGORIES:Infectious,Phase 2
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06943950-pcd@datacutoff.com
DTSTAMP:20261118T142521Z
DTSTART;VALUE=DATE:20270428
DTEND;VALUE=DATE:20270429
SUMMARY:SYHX1901 readout (P3) · CSPC Ouyi Pharmaceutical Co.\, Ltd. $1093.
 HK
DESCRIPTION:A Phase III Study of SYHX1901 Tablets in the Treatment of Moder
 ate to Severe Plaque Psoriasis\n\nPrimary completion date: 2027-04-28 (est
 imated)\nPhase 3 · Immuno · Moderate to Severe Plaque Psoriasis\nEnrollm
 ent: 500 · Sites: 0\n\nPrimary completion = last participant's primary-en
 dpoint data collected\; topline results usually follow weeks to months lat
 er. Sponsor-reported\, often an estimate. Not investment advice.\n\nhttps:
 //datacutoff.com/radar.html?nct=NCT06943950\nhttps://clinicaltrials.gov/st
 udy/NCT06943950
URL:https://datacutoff.com/radar.html?nct=NCT06943950
CATEGORIES:Immuno,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06947291-pcd@datacutoff.com
DTSTAMP:20261118T142521Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Glumetinib Tablets readout (P2) · CSPC ZhongQi Pharmaceutical Tech
 nology Co.\, Ltd. $1093.HK
DESCRIPTION:Safety and Efficacy of Glumetinib Combined With Docetaxel for I
 njection (Albumin-bound) in Patients With Advanced Gastric Cancer/Gastroes
 ophageal Junction Adenocarcinoma and Other…\n\nPrimary completion date: 
 2027-04-30 (estimated)\nPhase 2 · Oncology · Advanced Gastric Cancer/Gas
 troesophageal Junction Adenocarc…\nEnrollment: 350 · Sites: 1\n\nPrimar
 y completion = last participant's primary-endpoint data collected\; toplin
 e results usually follow weeks to months later. Sponsor-reported\, often a
 n estimate. Not investment advice.\n\nhttps://datacutoff.com/radar.html?nc
 t=NCT06947291\nhttps://clinicaltrials.gov/study/NCT06947291
URL:https://datacutoff.com/radar.html?nct=NCT06947291
CATEGORIES:Oncology,Phase 2
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07695597-pcd@datacutoff.com
DTSTAMP:20261118T142521Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:SYH2070 readout (P2) · CSPC Zhongnuo Pharmaceutical (Shijiazhuang)
  Co.\, Ltd. $1093.HK
DESCRIPTION:A Study of SYH2070 Injection in Participants With Mixed Hyperli
 pidemia\n\nPrimary completion date: 2027-04-30 (estimated)\nPhase 2 · Car
 dio-Met · Mixed Hyperlipidemia\nEnrollment: 240 · Sites: 1\n\nPrimary co
 mpletion = last participant's primary-endpoint data collected\; topline re
 sults usually follow weeks to months later. Sponsor-reported\, often an es
 timate. Not investment advice.\n\nhttps://datacutoff.com/radar.html?nct=NC
 T07695597\nhttps://clinicaltrials.gov/study/NCT07695597
URL:https://datacutoff.com/radar.html?nct=NCT07695597
CATEGORIES:Cardio-Met,Phase 2
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07798193-pcd@datacutoff.com
DTSTAMP:20261118T142521Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:SYH2085 readout (P2) · CSPC ZhongQi Pharmaceutical Technology Co.\
 , Ltd. $1093.HK
DESCRIPTION:A Study of SYH2085 Tablets Compared With Placebo in Chinese Adu
 lt Patients With Uncomplicated Influenza.\n\nPrimary completion date: 2027
 -04-30 (estimated)\nPhase 2 · Infectious · Influenza\nEnrollment: 213 ·
  Sites: 0\n\nPrimary completion = last participant's primary-endpoint data
  collected\; topline results usually follow weeks to months later. Sponsor
 -reported\, often an estimate. Not investment advice.\n\nhttps://datacutof
 f.com/radar.html?nct=NCT07798193\nhttps://clinicaltrials.gov/study/NCT0779
 8193
URL:https://datacutoff.com/radar.html?nct=NCT07798193
CATEGORIES:Infectious,Phase 2
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06562894-pcd@datacutoff.com
DTSTAMP:20261118T142521Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:SYHX1901 readout (P2) · CSPC Ouyi Pharmaceutical Co.\, Ltd. $1093.
 HK
DESCRIPTION:Study to Evaluate Safety and Efficacy of SYHX1901 Tablets in Se
 vere Alopecia Areata Patients\n\nPrimary completion date: 2027-05-31 (esti
 mated)\nOriginally planned: 2025-12-16 (+17.4 months)\nPhase 2 · Immuno 
 · Severe Alopecia Areata\nEnrollment: 156 · Sites: 0\n\nPrimary completi
 on = last participant's primary-endpoint data collected\; topline results 
 usually follow weeks to months later. Sponsor-reported\, often an estimate
 . Not investment advice.\n\nhttps://datacutoff.com/radar.html?nct=NCT06562
 894\nhttps://clinicaltrials.gov/study/NCT06562894
URL:https://datacutoff.com/radar.html?nct=NCT06562894
CATEGORIES:Immuno,Phase 2
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07623915-pcd@datacutoff.com
DTSTAMP:20261118T142521Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Bempedoic Acid Tablet readout (P3) · CSPC Ouyi Pharmaceutical Co.\
 , Ltd. $1093.HK
DESCRIPTION:A Clinical Study to Evaluate the Efficacy and Safety of Bempedo
 ic Acid\n\nPrimary completion date: 2027-06-30 (estimated)\nPhase 3 · Car
 dio-Met · Primary Hyperlipidemia\nEnrollment: 222 · Sites: 0\n\nPrimary 
 completion = last participant's primary-endpoint data collected\; topline 
 results usually follow weeks to months later. Sponsor-reported\, often an 
 estimate. Not investment advice.\n\nhttps://datacutoff.com/radar.html?nct=
 NCT07623915\nhttps://clinicaltrials.gov/study/NCT07623915
URL:https://datacutoff.com/radar.html?nct=NCT07623915
CATEGORIES:Cardio-Met,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07418736-pcd@datacutoff.com
DTSTAMP:20261118T142521Z
DTSTART;VALUE=DATE:20270701
DTEND;VALUE=DATE:20270702
SUMMARY:CM326 dose 1 readout (P2) · CSPC ZhongQi Pharmaceutical Technology
  Co.\, Ltd. $1093.HK
DESCRIPTION:A Phase II Study of CM326 in Subjects With Moderate to Severe C
 hronic Obstructive Pulmonary Disease\n\nPrimary completion date: 2027-07-0
 1 (estimated)\nPhase 2 · Respiratory · Chronic Obstructive Pulmonary Dis
 ease\nEnrollment: 318 · Sites: 1\n\nPrimary completion = last participant
 's primary-endpoint data collected\; topline results usually follow weeks 
 to months later. Sponsor-reported\, often an estimate. Not investment advi
 ce.\n\nhttps://datacutoff.com/radar.html?nct=NCT07418736\nhttps://clinical
 trials.gov/study/NCT07418736
URL:https://datacutoff.com/radar.html?nct=NCT07418736
CATEGORIES:Respiratory,Phase 2
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07591298-pcd@datacutoff.com
DTSTAMP:20261118T142521Z
DTSTART;VALUE=DATE:20270916
DTEND;VALUE=DATE:20270917
SUMMARY:SYH2070 injection dose1 readout (P2) · CSPC Zhongnuo Pharmaceutica
 l (Shijiazhuang) Co.\, Ltd. $1093.HK
DESCRIPTION:Phase II Clinical Trial to Evaluate the Efficacy and Safety of 
 SYH2070 Injection in Participants With Homozygous Familial Hypercholestero
 lemia\n\nPrimary completion date: 2027-09-16 (estimated)\nPhase 2 · Other
  · Diagnosed With HoFH\nEnrollment: 18 · Sites: 1\n\nPrimary completion 
 = last participant's primary-endpoint data collected\; topline results usu
 ally follow weeks to months later. Sponsor-reported\, often an estimate. N
 ot investment advice.\n\nhttps://datacutoff.com/radar.html?nct=NCT07591298
 \nhttps://clinicaltrials.gov/study/NCT07591298
URL:https://datacutoff.com/radar.html?nct=NCT07591298
CATEGORIES:Other,Phase 2
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07796477-pcd@datacutoff.com
DTSTAMP:20261118T142521Z
DTSTART;VALUE=DATE:20270928
DTEND;VALUE=DATE:20270929
SUMMARY:SYH2069 Injection (group 1) readout (P2) · CSPC Ouyi Pharmaceutica
 l Co.\, Ltd. $1093.HK
DESCRIPTION:A Study of SYH2069 Injection in Participants With T2DM Not Cont
 rolled With Diet/Exercise Alone or Metformin\n\nPrimary completion date: 2
 027-09-28 (estimated)\nPhase 2 · Cardio-Met · T2DM (Type 2 Diabetes Mell
 itus)\nEnrollment: 240 · Sites: 1\n\nPrimary completion = last participan
 t's primary-endpoint data collected\; topline results usually follow weeks
  to months later. Sponsor-reported\, often an estimate. Not investment adv
 ice.\n\nhttps://datacutoff.com/radar.html?nct=NCT07796477\nhttps://clinica
 ltrials.gov/study/NCT07796477
URL:https://datacutoff.com/radar.html?nct=NCT07796477
CATEGORIES:Cardio-Met,Phase 2
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07201688-pcd@datacutoff.com
DTSTAMP:20261118T142521Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:TRACE-LATE readout (P3) · CSPC Mingfule Pharmaceutical (Guangzhou)
  Co.\, Ltd. $1093.HK
DESCRIPTION:Phase III Clinical Trial of rhTNK-tPA in Treating Acute Ischemi
 c Stroke With Extended Time Window.\n\nPrimary completion date: 2027-09-30
  (estimated)\nPhase 3 · Cardio-Met · Acute Ischemic Stroke\nEnrollment: 
 890 · Sites: 1\n\nPrimary completion = last participant's primary-endpoin
 t data collected\; topline results usually follow weeks to months later. S
 ponsor-reported\, often an estimate. Not investment advice.\n\nhttps://dat
 acutoff.com/radar.html?nct=NCT07201688\nhttps://clinicaltrials.gov/study/N
 CT07201688
URL:https://datacutoff.com/radar.html?nct=NCT07201688
CATEGORIES:Cardio-Met,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07633873-pcd@datacutoff.com
DTSTAMP:20261118T142521Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:SYS6010 injection readout (P3) · CSPC Megalith Biopharmaceutical C
 o.\,Ltd. $1093.HK
DESCRIPTION:SYS6010 Combined With Enlonstobart Versus Immunotherapy+ Platin
 um-based Chemotherapy for Patients With PD-L1-Positive Locally Advanced or
  Metastatic NSCLC（SYNSTAR 04）\n\nPrimary completion date: 2027-09-30 (
 estimated)\nPhase 3 · Oncology · Non-Small Cell Lung Cancer\nEnrollment:
  500 · Sites: 0\n\nPrimary completion = last participant's primary-endpoi
 nt data collected\; topline results usually follow weeks to months later. 
 Sponsor-reported\, often an estimate. Not investment advice.\n\nhttps://da
 tacutoff.com/radar.html?nct=NCT07633873\nhttps://clinicaltrials.gov/study/
 NCT07633873
URL:https://datacutoff.com/radar.html?nct=NCT07633873
CATEGORIES:Oncology,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07803991-pcd@datacutoff.com
DTSTAMP:20261118T142521Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:SYH2069 Injection readout (P2) · CSPC Ouyi Pharmaceutical Co.\, Lt
 d. $1093.HK
DESCRIPTION:Efficacy and Safety of SYH2069 Injection in Obese Participants 
 Without Diabetes.\n\nPrimary completion date: 2027-09-30 (estimated)\nPhas
 e 2 · Cardio-Met · Overweight or Obesity\nEnrollment: 360 · Sites: 1\n\
 nPrimary completion = last participant's primary-endpoint data collected\;
  topline results usually follow weeks to months later. Sponsor-reported\, 
 often an estimate. Not investment advice.\n\nhttps://datacutoff.com/radar.
 html?nct=NCT07803991\nhttps://clinicaltrials.gov/study/NCT07803991
URL:https://datacutoff.com/radar.html?nct=NCT07803991
CATEGORIES:Cardio-Met,Phase 2
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
